Success Metrics

Clinical Success Rate
90.0%

Based on 9 completed trials

Completion Rate
90%(9/10)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Terminated
1(6%)

Phase Distribution

Ph phase_3
3
19%
Ph phase_1
1
6%
Ph phase_2
12
75%

Phase Distribution

1

Early Stage

12

Mid Stage

3

Late Stage

Phase Distribution16 total trials
Phase 1Safety & dosage
1(6.3%)
Phase 2Efficacy & side effects
12(75.0%)
Phase 3Large-scale testing
3(18.8%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

81.8%

9 of 11 finished

Non-Completion Rate

18.2%

2 ended early

Currently Active

0

trials recruiting

Total Trials

16

all time

Status Distribution
Completed(9)
Terminated(2)
Other(5)

Detailed Status

Completed9
unknown5
Withdrawn1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
16
Active
0
Success Rate
90.0%
Most Advanced
Phase 3

Trials by Phase

Phase 11 (6.3%)
Phase 212 (75.0%)
Phase 33 (18.8%)

Trials by Status

withdrawn16%
completed956%
unknown531%
terminated16%

Recent Activity

0 active trials
Showing 5 of 16
terminatedphase_2

Orathecin + Gemcitabine Versus Placebo + Gemcitabine in Chemonaive Non-Resectable Pancreatic Cancer

NCT00113256
completedphase_1

Study of Rubitecan in Cancer Patients With Renal or Hepatic Dysfunction

NCT00113113
completedphase_2

Nitrocamptothecin in Treating Patients With Metastatic Melanoma

NCT00005875
unknownphase_3

Nitrocamptothecin or Fluorouracil in Treating Patients With Recurrent or Refractory Pancreatic Cancer

NCT00005871
unknownphase_2

Nitrocamptothecin in Treating Patients With Locally Advanced or Metastatic Stomach Cancer That Cannot Be Removed During Surgery

NCT00005876
View all 16 trials

Clinical Trials (16)

Showing 16 of 16 trials
NCT00113256Phase 2

Orathecin + Gemcitabine Versus Placebo + Gemcitabine in Chemonaive Non-Resectable Pancreatic Cancer

Terminated
NCT00113113Phase 1

Study of Rubitecan in Cancer Patients With Renal or Hepatic Dysfunction

Completed
NCT00005875Phase 2

Nitrocamptothecin in Treating Patients With Metastatic Melanoma

Completed
NCT00005871Phase 3

Nitrocamptothecin or Fluorouracil in Treating Patients With Recurrent or Refractory Pancreatic Cancer

Unknown
NCT00005876Phase 2

Nitrocamptothecin in Treating Patients With Locally Advanced or Metastatic Stomach Cancer That Cannot Be Removed During Surgery

Unknown
NCT00005869Phase 3

Nitrocamptothecin Compared With Gemcitabine in Treating Patients With Unresectable Locally Advanced or Metastatic Pancreatic Cancer

Unknown
NCT00005870Phase 3

Nitrocamptothecin Compared With Other Chemotherapy in Treating Patients With Recurrent or Refractory Cancer of the Pancreas

Unknown
NCT00005872Phase 2

Nitrocamptothecin in Treating Patients With Recurrent Non-small Cell Lung Cancer

Completed
NCT00005877Phase 2

Nitrocamptothecin in Treating Patients With Advanced or Recurrent Colorectal Cancer

Unknown
NCT00005873Phase 2

Nitrocamptothecin in Treating Patients With Locally Recurrent or Metastatic Breast Cancer

Completed
NCT00005874Phase 2

Nitrocamptothecin in Treating Patients With Soft Tissue Sarcomas

Completed
NCT00006267Phase 2

Nitrocamptothecin in Treating Patients With Recurrent or Metastatic Ovarian Epithelial or Primary Peritoneal Cancer

Withdrawn
NCT00005826Phase 2

Nitrocamptothecin in Treating Patients With Glioblastoma Multiforme

Completed
NCT00006026Phase 2

Nitrocamptothecin in Treating Patients With Metastatic Cancer of the Urinary Tract

Completed
NCT00006230Phase 2

Nitrocamptothecin in Treating Patients With Advanced Ovarian Cancer

Completed
NCT00006082Phase 2

Nitrocamptothecin in Treating Patients With Advanced Small Cell Lung Cancer

Completed

All 16 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
16